{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-040183","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2023-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.297162+00:00","generated_at":"2026-06-19T11:12:03.571202+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Karyopharm grants annual equity awards to CEO Paulson and CFO Mason under 2022 Plan","bullets":["CEO Richard Paulson receives 252,000 time-based RSUs and 252,000 target PSUs (0-200% vesting).","CFO Michael Mason receives 95,000 time-based RSUs and 80,000 target PSUs.","PSU vesting tied 33% each to: 3-year revenue, 3 clinical milestones, and relative TSR vs Nasdaq Biotech Index.","Clinical milestone PSUs have a 1-year minimum vesting; performance measured over 3-year periods."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-040183","json":"https://secwatch.observer/filing/0001193125-23-040183.json","markdown":"https://secwatch.observer/filing/0001193125-23-040183.md","text":"https://secwatch.observer/filing/0001193125-23-040183.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312523040183/0001193125-23-040183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312523040183/d459493d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T11:12:03.571202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}